Skip to main content

HLB

HLB Co., Ltd. is a South Korean biopharmaceutical and healthcare enterprise that specializes in the development, clinical testing, and commercialization of targeted cancer therapies. The company operates through primary business segments including Biopharmaceutical Research, Healthcare Products, and Industrial Engineering. Its principal future revenue drivers stem from commercial sales of pharmaceutical candidates, targeted oncology treatments, licensing agreements, and healthcare device distribution. HLB Co., Ltd. holds a prominent market position in the South Korean biopharmaceutical industry, focusing heavily on its targeted anti-cancer drug candidate rivoceranib for various oncology indications. The enterprise conducts clinical development trials across global healthcare markets, collaborating with international research institutions and pharmaceutical partners. The company focuses on securing regulatory approvals for its oncology pipeline, expanding global licensing agreements, and advancing biopharmaceutical manufacturing operations. HLB Co., Ltd. is headquartered in Seoul, South Korea, and its common stock is publicly listed and traded on the KOSDAQ market of the Korea Exchange.

13 of the funds FundTelligence covers report a position in HLB.

Legal name
HLB Co. Ltd.
Sector
Health Care
Country
South Korea
Funds holding it
13

Funds holding HLB

Showing the 8 largest of 13 funds holding it.

Loading...